Evidence map›Paper›PMID 22672427›Full record

ArticleBMC cancer2012

Concurrent epigenetic silencing of wnt/β-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia.

Evgeny A Moskalev, Katrin Luckert, Ivan A Vorobjev, Sergey E Mastitsky, Aleena A Gladkikh, Achim Stephan, Marita Schrenk, Kamil D Kaplanov, Olga B Kalashnikova, Oliver Pötz and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 46 citations in OpenAlex.

  1. Wnt signaling - using the bloodstream to send a message.Cellular and molecular life sciences : CMLS · 2025
    Review
  2. Expression ofInternational journal of molecular sciences · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. The physiological role of Wnt pathway in normal development and cancer.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Wnt signaling in cancer.Oncogene · 2017
    Review
  20. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Evgeny A MoskalevFunctional Genome Analysis, Deutsches Krebsforschungszentrum, Heidelberg, Germany. evgeny.moskalev@uk-erlangen.de
Katrin Luckert
Ivan A Vorobjev
Sergey E Mastitsky
Aleena A Gladkikh
Achim Stephan
Marita Schrenk
Kamil D Kaplanov
Olga B Kalashnikova
Oliver Pötz
Thomas O Joos
Jörg D Hoheisel
DKFZ-ZMBH Alliance · DENatural and Medical Sciences Institute · DEVolgograd Regional Clinical Oncology Center · RUFederal State Institution Hematology Research Center · RUGerman Cancer Research Center · DEHeidelberg University · DELomonosov Moscow State University · RUUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Wnt/β-catenin signalling is aberrantly activated in primary B cell chronic lymphocytic leukaemia (CLL). Epigenetic silencing of pathway inhibitor genes may be a mechanism for its activation. In this study, we investigated systematically and quantitatively the methylation status of 12 Wnt/β-catenin pathway inhibitor genes - CDH1, DACT1, DKK1, DKK2, DKK3, DKK4, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5 and WIF1 - in the cell lines EHEB and MEC-1 as well as patient samples.

methodsQuantification of DNA methylation was performed by means of bisulphite pyrosequencing and confirmed by bisulphite Sanger sequencing. Gene expression was analysed by qPCR using GAPDH as internal control. E-cadherin and β-catenin protein quantification was carried out by microsphere-based immunoassays. Methylation differences observed between the patient and control groups were tested using generalised least squares models.

resultsFor 10 genes, a higher methylation level was observed in tumour material. Only DKK4 exhibited similarly high methylation levels in both tumour and normal specimens, while DACT1 was always essentially unmethylated. However, also for these inhibitors, treatment of cells with the demethylating agent 5-aza-2´-deoxycytidine resulted in an induction of their expression, as shown by quantitative PCR, suggesting an indirect epigenetic control of activity. While the degree of demethylation and its transcriptional consequences differed between the genes, there was an overall high correlation of demethylation and increased activity. Protein expression studies revealed that no constitutive Wnt/β-catenin signalling occurred in the cell lines, which is in discrepancy with results from primary CLL. However, treatment with 5-aza-2´-deoxycytidine caused accumulation of β-catenin. Simultaneously, E-cadherin expression was strongly induced, leading to the formation of a complex with β-catenin and thus demonstrating its epigenetically regulated inhibition effect.

conclusionsThe results suggest an epigenetic silencing mechanism of the Wnt/β-catenin pathway inhibitor genes in CLL. Hypermethylation and silencing of functionally related genes may not be completely stochastic but result from the tumour epigenome reprogramming orchestrated by Polycomb-group repressive complexes. The data are of interest in the context of epigenetic-based therapy.

Indexed as

Epigenesis, GeneticGene SilencingSignal TransductionAntimetabolites, AntineoplasticAzacitidinebeta CateninCadherinsCell Line, TumorChromosome MappingCpG IslandsDNA MethylationGene Expression Regulation, NeoplasticHumansLeukemia, Lymphocytic, Chronic, B-CellProtein BindingWnt ProteinsAntimetabolites, AntineoplasticAzacitidinebeta CateninCadherinsWnt Proteins

Identifiers

PMID22672427
PMCPMC3489542
OpenAlexW2160157929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.